United States Patent 9,284,342 Scope, Claims Breakdown, and Landscape: Crystalline SP-4 for Hepatitis C (XRPD 6.1°/12.7°)
Executive summary: U.S. Patent 9,284,342 centers on a specific crystalline form of an SP-4 compound defined by an XRPD profile with key reflections at about 6.1° and 12.7°. It claims (i) the crystalline material itself, (ii) pharmaceutical compositions, (iii) human treatment of hepatitis C virus (HCV) infection, (iv) combination treatment with another antiviral, and (v) multiple preparation routes tied to humidity exposure, grinding and open-vessel standing, and aqueous suspension with heating and cooling. The enforceable claim surface is strongest where competitors rely on the same solid-state form or an infringing polymorph equivalent that maintains the XRPD hallmark. The risk profile for generic or next-gen entrants is driven by whether they can prove the commercial material is not the claimed crystalline form under XRPD criteria, and whether they can design around the preparation steps that recreate the SP-4 form.
What does US Patent 9,284,342 claim and how broad is its crystalline SP-4 definition?
Core claim anchor: A “crystalline compound” represented by a specific formula labeled (SP-4), where the crystalline identity is established by XRPD 2θ reflections “at about 6.1 and 12.7.”
What that buys the patent holder
- Form-of-material control: The patent does not claim “any crystalline form” of the API, it claims a crystalline form whose XRPD pattern includes the stated peaks. That is a form-based right that can extend beyond the original example lot if other products reproduce the same solid-state signature.
- Claim leverage in solids competition: Even if competitors use the same active molecule, infringement pivots on whether their solid form matches the claimed XRPD-defined pattern.
- Multi-environment coverage: The patent covers material, compositions, therapeutic use, and manufacturing-style processes that lead to the form.
What narrows the patent
- XRPD requirement acts as a gating limitation: If competitors’ material has the same formula but shows a materially different diffraction pattern (or lacks the key peaks), they can potentially exit claim scope.
- XRPD “about” introduces tolerance but still constrains: “About 6.1 and 12.7” gives some experimental wiggle room but not an unlimited range.
- The SP-4 formula is not described in your prompt: Without the chemical identity of SP-4, the “formula” term itself is a hard boundary. Competitors using different chemical entities may not be captured even if the peaks match.
How do XRPD peak requirements affect infringement analysis?
For XRPD-defined polymorph claims, courts and examiners typically focus on whether the accused product’s diffraction pattern meets the claimed “at about” reflections with sufficient match under the patent’s instructions, figure references, or example methodology. Since your claim set explicitly references FIG. 3/FIQ. 4 patterns for preparation steps, the claim interpretation likely treats the diffraction profile as central to identity.
Typical infringement/invalidity pressure points for XRPD claims
- Method dependency: XRPD instrument settings, sample preparation (drying, air exposure), grain size, and baseline subtraction can shift peak positions.
- Peak presence vs. peak dominance: The claim says “having XRPD 2θ-reflections at about 6.1 and 12.7.” If a competitor’s material shows those peaks but at low intensity, the issue becomes whether “having reflections” requires a certain intensity or just detectability.
- Polymorph mixtures: Partial transformation can create superimposed patterns. If mixtures contain the claimed form, infringement exposure increases for composition claims, but process claims can depend on how the final material is produced and isolated.
Which claims cover product, which cover use, and which cover manufacturing processes?
A. Product and composition claims
- Claim 1: Crystalline compound, SP-4 with XRPD peaks at about 6.1 and 12.7.
- Claim 2: Pharmaceutical composition comprising the crystalline compound of claim 1 plus a pharmaceutically acceptable medium.
Practical effect: If a competitor sells a formulation containing the claimed crystalline form, claim 2 can be asserted even if their manufacturing process is not identical to your claim 5–9, as long as their marketed solid is the claimed XRPD form.
B. Method-of-treatment claims
- Claim 3: Treating HCV infection in a human by administering an effective amount of the crystalline compound.
- Claim 4: Claim 3 plus administering another antiviral agent (combination therapy).
Practical effect: The method claims capture clinical administration, including fixed-dose and co-administration regimes, provided the administered API is the claimed crystalline form.
C. Process claims (solid-state manufacturing)
- Claim 5: Preparing the crystalline compound by exposing a “second crystalline compound” (also labeled SP-4 but defined by FIG. 3/FIQ. 4 diffraction) to atmospheric humidity to provide a first composition.
- Claim 6: Further: grinding into a powder and allowing the powder to stand in an open vessel.
- Claim 7: Preparing by suspending the second crystalline compound in water to provide a suspension.
- Claim 8: Further: heating the suspension.
- Claim 9: Further: cooling the suspension.
Practical effect: These are process path dependencies that can be used for enforcement where direct product testing is contested, and also create leverage against contract manufacturers (CMOs) whose workflows map onto these steps.
How do process claims interact with product-by-process defenses?
For XRPD polymorph patents, even if a competitor uses a different process, they can still infringe product claims if their final product is the claimed crystalline form. Conversely, competitors can avoid process claim exposure but still face product and composition claim risk if their marketed crystalline material matches the XRPD definition.
What is the scope of “another antiviral agent” in combination claim 4?
Claim 4 scope: “Further comprising administering to the human another antiviral agent” alongside the SP-4 crystalline compound.
Breadth drivers
- The claim does not limit the class, mechanism, target, or identity of the “another antiviral agent.”
- It does not limit the dosing form or schedule (simultaneous vs. sequential is not specified in your text).
- It is not restricted to specific HCV genotypes, line of therapy, or patient characteristics in your provided claim language.
Enforcement implication: Combination infringement risk increases if the marketed regimen pairs the SP-4 compound with any HCV antiviral (including direct acting antivirals and auxiliary agents) under a label that aligns with the claim.
How strong is the patent estate for HCV crystalline solids defined by XRPD peaks?
Given the claim architecture, U.S. 9,284,342 is structurally a solid-form “primary” patent with:
- material claim (claim 1),
- formulation claim (claim 2),
- use claim (claims 3–4),
- manufacturing/process claims (claims 5–9).
This set is typically stronger than a use-only patent because it creates multiple independent assertion theories against the same infringing commercial fact pattern: sale of the crystalline solid, sale of a formulation containing it, and administration of it for HCV.
What strengthens validity
- XRPD peak-based identity can be defended as a precise physical characterization, which can support novelty and non-obviousness of a particular polymorph/form.
What weakens validity
- If earlier publications disclose the same crystalline form (SP-4) and report the same XRPD peaks, claim 1 becomes vulnerable.
- If earlier patents already claim the crystalline form using equivalent XRPD definitions, claim scope overlaps with prior art.
- If SP-4 is known as an HCV antiviral active, prior art may attack the method-of-treatment and combination claims as obvious once the crystalline form is known (or vice versa).
How could competitors design around claim 1’s XRPD definition (6.1° and 12.7°)?
Design-around pathways
- Different polymorph/material: Deliver a different crystalline form that does not include both peaks at the claimed “about” locations.
- Amorphous or co-amorphous form: If amorphous, XRPD lacks sharp peaks at 2θ values characteristic of a crystalline lattice, potentially exiting claim 1.
- Crystalline mixture engineering: If a competitor uses a mixture where the SP-4 form is absent or below detectability, it may avoid “having” the peaks.
- Peak shift via processing: Drying, milling, humidity cycling, and thermal history can change peak positions; if the peaks shift beyond the “about” range, infringement risk drops.
Commercial reality constraint: Most solid-state engineering is bounded by manufacturability and regulatory expectations. A competitor may accept a slight XRPD mismatch if it still meets quality specs, but if regulators or customers require tight similarity to the reference product, design-around may be costly.
What patents are likely in the surrounding landscape (polymorph/formulation/process/method) and how do they layer with 9,284,342?
Even without the full patent family list in your prompt, the claim content indicates typical family members and continuation strategy:
- Polymorph patents covering alternate forms with different XRPD signatures.
- Solvates/hydrates defined by characteristic XRPD and/or thermal events.
- Compositions with specific excipient systems, particle-size ranges, or solid dispersions.
- Processes that convert one form to another using controlled humidity, slurry conversion, precipitation, heating/cooling ramps.
- Method-of-use patents tying the active to HCV regimens and particular combinations.
Landscape impact: If U.S. 9,284,342 is a crystalline-form core, competitors will often challenge:
- the existence of the specific claimed form in the accused product,
- the novelty/non-obviousness of the form,
- and whether earlier publications or patents anticipate the XRPD-defined identity.
What does claim scope imply for Orange Book status and FDA regulatory exclusivity?
Your prompt does not provide the drug’s name, NDA/BLA number, or Orange Book listing status. Without those identifiers, the regulatory-exclusivity linkage cannot be mapped to a specific product entry.
Operationally, however, XRPD polymorph patents that claim a crystalline active form often attach to:
- the NDA product that contains that crystalline solid,
- associated formulation changes,
- and sometimes to manufacturing controls in the submission.
Regulatory risk implication for generics: If the approved drug uses the crystalline SP-4 form, ANDA filers can face a high “carve-out” burden. A Paragraph IV challenge typically requires an invalidity/non-infringement theory grounded in XRPD differences and process divergence.
What generic entry risks exist under ANDA for an XRPD-defined crystalline HCV drug?
High risk scenario: The ANDA applicant’s product contains the same SP-4 crystalline form and therefore infringes claim 1 and claim 2, regardless of how it is manufactured.
Lower risk scenario: The ANDA applicant uses a different form or amorphous form that:
- fails to show the claimed XRPD reflections at about 6.1 and 12.7, and
- avoids process steps that are keyed to conversion to the SP-4 form.
Litigation leverage point: Even if a generic applicant can produce a non-infringing form, it may still face method-of-use exposure if the approved labeling or promotional materials direct use for HCV treatment consistent with claims 3–4. Label design and carve-outs become central if method claims remain enforceable.
How would a Paragraph IV challenge likely be structured for US 9,284,342?
Typical non-infringement strategy for XRPD claims
- Test accused product solids for XRPD peaks: absence or shift beyond “about” 6.1 and 12.7.
- Demonstrate the accused solid is not crystalline SP-4 but a different polymorph/solvate/amorphous variant.
- Challenge assay repeatability and detection: show that under standardized conditions, the peaks do not occur as required.
Typical invalidity strategy
- Locate prior art disclosing the same crystalline SP-4 form with the same XRPD signature.
- Attack the claim for lack of novelty (anticipation) or obviousness based on known polymorph conversion methods using humidity, slurry conversion, heating, and cooling.
- Attack broad method claims (HCV treatment) if the active molecule’s use in HCV is already known.
Process claims specific vulnerability
- If prior art shows humidity exposure, grinding/open-vessel standing, and slurry heating/cooling producing the same crystalline form, process claims can be vulnerable to obviousness.
Key claim-to-design-around matrix for infringement triage
| Patent claim |
What it requires (per your text) |
Main infringement evidence |
Main design-around levers |
| Claim 1 |
Crystalline SP-4; XRPD peaks at about 6.1° and 12.7° |
XRPD of accused API lots |
Use different polymorph/solvate/amorphous; shift peak positions; avoid the specific crystalline form |
| Claim 2 |
Pharmaceutical composition containing claim 1 crystalline compound |
Formulation composition + API form |
Formulate with non-infringing solid; different crystalline form |
| Claim 3 |
Administer crystalline compound to treat HCV |
Labeling, prescribing, patient administration |
Use different form not covered by claim 1; adjust label to avoid claim-aligned administration |
| Claim 4 |
Claim 3 plus another antiviral agent |
Regimen combination and labeling |
Avoid combinations captured by claim 4 via label/carve-outs and/or non-infringing API |
| Claim 5 |
Convert second crystalline compound to first composition via atmospheric humidity exposure |
Manufacturing steps + product form |
Use alternative conversion route that avoids this step or yields non-SP-4 form |
| Claim 6 |
Grind powder and stand in open vessel |
CM steps + product form |
Use closed-vessel control, different milling/aging regime |
| Claim 7 |
Suspend second crystalline compound in water |
CM steps + product form |
Use different solvent/route or avoid creating the same intermediate transformation |
| Claim 8 |
Heat suspension |
CM steps + product form |
Change temperature profile/ramp; use alternate crystallization conditions |
| Claim 9 |
Cool suspension |
CM steps + product form |
Change cooling conditions to avoid forming claimed crystalline SP-4 |
What litigation and settlement dynamics typically matter for polymorph patents like 9,284,342?
Polymorph cases often settle around:
- testing protocols (XRPD sampling, instrument settings),
- burden of proof on identity of solid form,
- and stipulated non-infringing designs (different polymorph target or production route).
Because claim 1 is XRPD-defined, disputes often narrow to whether the accused product meets the peak criteria and whether “about” allows the accused peaks.
How to assess patent strength for licensing or investment based on claim mechanics
Strength indicators in this claim set
- Multiple claim categories (material, composition, method, process) reduce the chance that an opponent invalidates one pathway and automatically wins.
- XRPD definition gives a concrete, testable identity that can be used in both infringement and validity debates.
- Combination claim 4 expands coverage even if monotherapy arguments weaken.
Weakness indicators typically assessed
- Whether prior art already identifies the same crystalline form by XRPD peaks and uses it for HCV.
- Whether the XRPD definition is sufficiently supported in the specification and whether “about” is construed narrowly or broadly.
- Whether process claims are duplicative of known humidity/slurry conversion techniques.
Key Takeaways
- U.S. 9,284,342 is a crystalline-form patent for an HCV-relevant SP-4 compound, defined by XRPD peaks “about 6.1° and 12.7°.”
- The enforceable scope spans product (claim 1), formulation (claim 2), HCV method-of-use (claims 3–4), and multiple manufacturing conversion routes tied to humidity exposure and water slurry heating/cooling (claims 5–9).
- The primary infringement question is whether the accused commercial solid matches the XRPD identity of the claimed SP-4 form; secondary questions include label-driven method-of-use exposure and whether process steps reproduce the conversion pathway.
- Generic entry risk is dominated by the ability to demonstrate a non-infringing solid form and to avoid combination and labeling theories tied to HCV treatment.
FAQs
1) What does “XRPD 2θ reflections at about 6.1 and 12.7” mean for testing?
It means infringement analysis turns on whether the accused crystalline material’s X-ray diffraction pattern shows the claimed peaks at approximately those 2θ angles under the relevant test conditions.
2) Can a competitor avoid claim 1 by using the same drug in an amorphous form?
Yes, if the amorphous material lacks the crystalline reflections required by the claim definition and therefore does not “have” the XRPD peaks as required.
3) Does claim 2 allow infringement even if manufacturing steps differ?
Yes. Composition claims generally require only that the marketed formulation contains the claimed crystalline compound, not that it was made using the specific process steps.
4) How broad is claim 4’s “another antiviral agent”?
Broad. The claim text does not limit the identity or class of the additional antiviral, so pairing with other HCV antivirals can fall within its scope if the crystalline compound is administered for HCV treatment.
5) Which claim is most likely to be targeted in an ANDA Paragraph IV challenge for XRPD polymorph patents?
Claim 1 (and downstream claim 2) is typically the first target through non-infringement testing of the accused solid form using XRPD identity criteria.
References (APA)
- U.S. Patent 9,284,342.
